PF 6883541
Alternative Names: PF-06883541; PF-6883541Latest Information Update: 28 Oct 2019
At a glance
- Originator Cellectis
- Developer Allogene Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Cancer in USA (Parenteral)
- 09 Apr 2018 Allogene Therapeutics acquires PF 6883541 from Pfizer (Pfizer pipeline, May 2018)
- 03 Apr 2018 Allogene and Pfizer enter into an asset contribution agreement for allogeneic chimeric antigen receptor T-cell therapy iincluding 16 preclinical CAR-T assets